Replimune Group, Inc.
REPLHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The $732.4M market capitalization puts REPL squarely in small-cap range for its industry. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Market Cap
$732.4M
Beta
0.12
P/E (TTM)
—
P/E (Fwd)
-4.30
EPS (TTM)
$-3.44
EPS (Fwd)
$-2.06
ROE
-90.9%
ROA
-43.2%
Cash
$269.1M
Total Debt
$76.3M
Free CF
-$172.8M
52W Change
-8.5%
Annual Financials
Cash vs Debt
With $269.1M in cash and $76.3M in debt, REPL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$172.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -90.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
REPL's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing REPL.